Dronabinol - Vertanical GmbH
Alternative Names: delta-9-Tetrahydrocannabinol; VER-01Latest Information Update: 08 Jul 2024
At a glance
- Originator Vertanical
- Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Back pain
Most Recent Events
- 30 Jun 2024 Vertanical GmbH plans the phase II RESPONSE trial Back pain (PO), in June 2024 (NCT06475001) (EudraCT2023-507358-34)
- 26 Mar 2024 Vertanical completes a Phase-III clinical trials in Back pain in Germany, Austria (PO) (EudraCT-2020-000107-36) (NCT04940741)
- 27 Feb 2023 Phase-III clinical trials in Back pain in Spain (PO) (NCT05610813) (EudraCT2022-001358-41)